Patent number: 7268095
Abstract: A compound of the formula Ia or Ib; where, in the formula Ia, E1 is O, S, Se, Te, NR, CR2, or PR; E2, E3 are each CR, N, or P; E4 is N, or P; E5 is OH, SH, NHR, OR?, SR?, or NRR?; E6 is NH, PH, NR?, or PR?; R5, R6 are each hydrogen or a linear, branched or cyclic alkyl radical or an aryl radical; R1, R2, R3, R4 are each hydrogen, a linear, branched or cyclic alkyl radical, an aryl radical, a halogen or a nitro group; R is hydrogen, a linear, branched or cyclic alkyl radical; R? is a linear, branched or cyclic alkyl radical; where at least one of the groups E5 and E6 contains a hydrogen atom; and in the formula Ib, the symbols E1, E4, E5, E6, R5, R6, R1, R2, R3, R4, R and R? are as defined in formula Ia; and E?2 and E?3 are each O, S, Se, Te, NR, CR2, or PR.
Type:
Grant
Filed:
November 3, 2003
Date of Patent:
September 11, 2007
Assignee:
Basell Polyolefine GmbH
Inventors:
Peter Preishuber-Pflügl, Jun Okuda, Valentine Reimer, Marc Oliver Kristen
Patent number: 6855722
Abstract: The present invention relates to novel substituted indole compounds that are antagonists of alpha V (?v) integrins, for example ?v?3 and ?v?5 integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by ?v?3 and ?v?5 integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula: where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, D, X, W, a, m, n, i, j, k and v are defined herein.
Type:
Grant
Filed:
January 29, 2002
Date of Patent:
February 15, 2005
Assignee:
Dimensional Pharmaceuticals, Inc.
Inventors:
Tianbo Lu, Louis V. LaFrance, Thomas P. Markotan, Juan J. Marugan Sanchez, Victor J. Marder, David C. U'Prichard, Beth M. Anaclerio, Zihong Guo, Wenzi Pan, Kristi A. Leonard, Bruce E. Tomczuk